钆布醇增强磁共振血管造影术在平衡期对胸段血管的成像：可行性及剂量影响
Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.
作者信息
Kim Charles Y, Heye Tobias, Bashir Mustafa R, Gebhard Thomas A, Merkle Elmar M
机构信息
From the *Department of Radiology, Duke University Medical Center, Durham, NC; and †Department of Radiology, University Hospital of Basel, Basel, Switzerland.
出版信息
J Comput Assist Tomogr. 2013 Sep-Oct;37(5):732-6. doi: 10.1097/RCT.0b013e318299dde9.
OBJECTIVE
The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality.
METHODS
Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed.
RESULTS
At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses.
CONCLUSIONS
Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.This trial was registered with clinicaltrials.gov, identifier NCT01431300.
目的
本研究的目的是评估平衡期钆布醇增强磁共振血管造影（MRA）对胸部血管成像的可行性，并确定钆布醇剂量对成像质量的影响。
方法
30名健康志愿者被随机分为三组，分别接受0.03、0.02或0.01 mmol/kg剂量的钆布醇，在3 T场强下进行平衡期胸部血管MRA检查。两名放射科医生对中心静脉、肺动脉和胸主动脉进行评估，并进行定量分析。
结果
0.03和0.02 mmol/kg剂量组，所有血管节段均被评为图像质量合格。0.01 mmol/kg剂量组，不到10%的血管节段被评为图像质量不合格。与高剂量组相比，0.01 mmol/kg剂量组所有血管节段的信噪比和对比噪声比均显著降低。
结论
即使降低剂量，钆布醇增强MRA在健康志愿者平衡期对胸部血管成像时，仍能获得足够的血管显影。本试验已在clinicaltrials.gov注册，标识符为NCT01431300。
Zotero 插件